Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Neurizon Therapeutics Limited (NUZ) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of Neurizon Therapeutics Limited A$0.03, price A$0.08, upside -69.9%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
NT
Thin data
Oct 14, 2026
Neurizon Therapeutics Limited
NUZ · AUWeakest SetupStrongly overvalued and low quality.
Our calculation puts a fair price 70% below what the stock costs today.
Quality 42/100
Mixed Growth (revenue 5y +39.1 %/yr in AUD)
Fair value A$0.0253 · Strongly overvalued (−69.9%)
Loss-making · -61.0% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 0/100
Thin data
⚠ Dilution
Watch Neurizon Therapeutics Limited for free: we tell you when fair value or trend changes.
Watch for free
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 14, 2026.
How to read this chart
60‑month range A$0.0550 – A$0.4179 · fair‑value band A$0.0181 – A$0.0253 · the A$0.0840 price screens above the A$0.0253 fair value. Dashed = 300-day average. As of Oct 14, 2026.
Follow Neurizon Therapeutics in your weekly email
Every Wednesday you see whether Neurizon Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia.
Show more
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Stock analysis
Neurizon Therapeutics Limited (NUZ) currently trades at A$0.0840, while our model-based Fair Value estimate is A$0.0253, 69.9% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: A$0.0181 (bear) to A$0.0253 (bull), the price of A$0.0840 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Neurizon Therapeutics Limited reported revenue of A$17.6M in FY2026 versus A$3.2M in FY2020, a compound +32.9%/yr. Reported net income was −A$10.7M in FY2026.
Key figures
Market cap A$63.7M (≈ $44.6M) · P/S ratio 3.83 · EPS (TTM) A$−0.0200 · Net margin −61.0% · Return on equity −138% · Return on assets (EBIT) −151% · Operating margin −40.8% · Revenue (TTM) A$17.6M.
What moves the price
The share trades about 41% below its 52-week high and 53% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −70%, NUZ screens richer than that median.
Fair Value models
Bear A$0.0181
Fair Value A$0.0253
Bull A$0.0253
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham)
A$0.0100
A$0.0100
A$0.0200
50
All 1 models by family
Asset-Based
NCAV (Graham)
A$0.0100
A$0.0100
A$0.0200
50
Quality Score breakdown
Overall quality
42/100
Of which business quality 42 · Market factors (momentum, volatility) 30
Profitability
30
Margins and returns on capital today
Quality Growth
99
Are margins and returns improving?
Cashflow
20
Earnings quality: real cash, not paper profit
Fin. Strength
70
Balance sheet, leverage, solvency risk
Investment
33
Disciplined investing over empire-building
Low Volatility
23
Calm price path (market factor)
Momentum
42
Price trend over the last 3–12 months (market factor)
52W Momentum
17
Distance to the 52-week high (market factor)
Net Issuance
0
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.1%
Start year 2021 (pandemic). Over 10 years: +19.9% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.3%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−81.3% (2021) → −157.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Compare Neurizon Therapeutics Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Valuation of the Australia market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $746.54 | $1,275 | +71% | vs NUZ |
| Vertex Pharmaceuticals Incorporated VRTX | $510.08 | $561.09 | +10% | vs NUZ |
| argenx SE ARGX | $825.03 | $907.53 | +10% | vs NUZ |
| Samsung Biologics Co 207940 | 1,219,000 KRW | 1,340,900 KRW | +10% | vs NUZ |
| WuXi Biologics (Cayman) Inc 2269 | HK$52.65 | HK$57.92 | +10% | vs NUZ |
| CSL Limited CSL | A$181.46 | A$179.90 | −1% | vs NUZ |
| Alnylam Pharmaceuticals, Inc ALNY | $232.68 | $217.88 | −6% | vs NUZ |
| BeOne Medicines AG ONC | $354.47 | $280.94 | −21% | vs NUZ |
| Celltrion, Inc 068270 | 180,400 KRW | 74,519 KRW | −59% | vs NUZ |
| Royalty Pharma plc RPRX | $56.93 | $19.01 | −67% | vs NUZ |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Neurizon Therapeutics Limited (NUZ) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of A$0.0253 versus a price of A$0.0840, about −70% upside (overvalued).
What is the fair value of NUZ?
Our model-based fair value for Neurizon Therapeutics Limited is A$0.0253 (as of Oct 14, 2026), built from audited fundamentals. The current price: A$0.0840.
What is the quality score of NUZ?
Neurizon Therapeutics Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neurizon Therapeutics Limited (NUZ)?
Our model-based price target is the fair value of A$0.0253 (as of Oct 14, 2026) from 1 valuation models. Cautious scenario A$0.0181, optimistic scenario A$0.0253. It is a calculation from audited fundamentals, not an analyst target.
What is the Neurizon Therapeutics Limited stock forecast for 2026?
Our models put fair value at A$0.0253, about −70% upside versus a price of A$0.0840 (overvalued). Cautious scenario A$0.0181, optimistic scenario A$0.0253. The calculation is refreshed regularly with new filings.
What is the revenue of Neurizon Therapeutics Limited (NUZ)?
Neurizon Therapeutics Limited reported trailing-twelve-month revenue of about A$17.6M (latest available figure, as of Oct 14, 2026).
What is the intrinsic value of Neurizon Therapeutics Limited (NUZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neurizon Therapeutics Limited it is A$0.0253 per share (as of Oct 14, 2026), against a price of A$0.0840. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Neurizon Therapeutics Limited stock overvalued or undervalued in 2026?
As of Oct 14, 2026, NUZ trades above its calculated fair value: price A$0.0840, fair value A$0.0253, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NUZ?
No. The price is what the market pays today (A$0.0840); the fair value is what the company's own numbers justify (A$0.0253). For Neurizon Therapeutics Limited the two are A$0.0587 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neurizon Therapeutics Limited worth?
The market values Neurizon Therapeutics Limited at about A$63.7M (market capitalisation, as of Oct 14, 2026). Per share that is A$0.0840; our models calculate a fair value of A$0.0253 per share.
What do the bullish and bearish scenarios say about NUZ?
Our models span a range for Neurizon Therapeutics Limited: cautious scenario A$0.0181, base A$0.0253, optimistic A$0.0253 per share (as of Oct 14, 2026, price A$0.0840). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of NUZ?
The PEG ratio of Neurizon Therapeutics Limited is 0.76 (P/E divided by earnings growth, as of Oct 14, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Neurizon Therapeutics Limited (NUZ)?
Balance-sheet figures for Neurizon Therapeutics Limited (as of Oct 14, 2026): return on equity −137.9%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is NUZ from its 52-week high?
Neurizon Therapeutics Limited trades at A$0.0840, about 41% below its 52-week high of A$0.1426 and 53% above the low of A$0.0550 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0253 is for.
Which stocks are comparable to Neurizon Therapeutics Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neurizon Therapeutics Limited stock attractive at the current price?
The data as of Oct 14, 2026: price A$0.0840, calculated fair value A$0.0253 (−70%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NUZ calculated?
We run Neurizon Therapeutics Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0253, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Neurizon Therapeutics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neurizon Therapeutics Limited (NUZ)?
The closing price on Oct 14, 2026 was A$0.0840. Our model-based fair value is A$0.0253, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neurizon Therapeutics Limited right now?
The price sits above even our optimistic bull case (A$0.0253). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Neurizon Therapeutics Limited
How large is the market capitalisation of Neurizon Therapeutics Limited (NUZ)?
The market capitalisation of Neurizon Therapeutics Limited is A$63.7M (≈ $44.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neurizon Therapeutics Limited (NUZ)?
The price-to-sales ratio of Neurizon Therapeutics Limited is 3.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neurizon Therapeutics Limited (NUZ)?
Earnings per share at Neurizon Therapeutics Limited are A$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neurizon Therapeutics Limited (NUZ)?
The net margin of Neurizon Therapeutics Limited is −61.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neurizon Therapeutics Limited (NUZ)?
The return on equity (ROE) of Neurizon Therapeutics Limited is −138% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neurizon Therapeutics Limited (NUZ)?
On an EBIT basis the return on assets of Neurizon Therapeutics Limited is −151% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neurizon Therapeutics Limited (NUZ)?
The operating margin of Neurizon Therapeutics Limited is −40.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Neurizon Therapeutics Limited (NUZ) generate?
The free cash flow of Neurizon Therapeutics Limited is −A$15.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Neurizon Therapeutics Limited (NUZ) hold?
Neurizon Therapeutics Limited holds more cash than debt, A$9.4M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Neurizon Therapeutics Limited in the live analysis
One click puts Neurizon Therapeutics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.